ConvaTec Group (CTEC) Competitors

GBX 275.60
-9.40 (-3.30%)
(As of 04:35 PM ET)

CTEC vs. HIK, SN, HCM, INDV, AMS, TSTL, BVC, SPEC, CNSL, and GNS

Should you be buying ConvaTec Group stock or one of its competitors? The main competitors of ConvaTec Group include Hikma Pharmaceuticals (HIK), Smith & Nephew (SN), HUTCHMED (HCM), Indivior (INDV), Advanced Medical Solutions Group (AMS), Tristel (TSTL), BATM Advanced Communications (BVC), INSPECS Group (SPEC), Cambridge Nutritional Sciences (CNSL), and Genus (GNS). These companies are all part of the "medical" sector.

ConvaTec Group vs.

Hikma Pharmaceuticals (LON:HIK) and ConvaTec Group (LON:CTEC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.

Hikma Pharmaceuticals pays an annual dividend of GBX 57 per share and has a dividend yield of 3.1%. ConvaTec Group pays an annual dividend of GBX 5 per share and has a dividend yield of 1.8%. Hikma Pharmaceuticals pays out 8,507.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,068.75, indicating a potential upside of 12.54%. ConvaTec Group has a consensus price target of GBX 307.17, indicating a potential upside of 11.45%. Given ConvaTec Group's higher possible upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than ConvaTec Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
ConvaTec Group
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Hikma Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, ConvaTec Group has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

Hikma Pharmaceuticals has a net margin of 6.61% compared to Hikma Pharmaceuticals' net margin of 6.08%. ConvaTec Group's return on equity of 8.81% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals6.61% 8.81% 8.46%
ConvaTec Group 6.08%7.89%4.79%

In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than ConvaTec Group. MarketBeat recorded 3 mentions for Hikma Pharmaceuticals and 0 mentions for ConvaTec Group. ConvaTec Group's average media sentiment score of 0.77 beat Hikma Pharmaceuticals' score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Hikma Pharmaceuticals Positive
ConvaTec Group Neutral

Hikma Pharmaceuticals has higher revenue and earnings than ConvaTec Group. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£2.88B1.42£190M£0.672,743.56
ConvaTec Group£2.14B2.64£130.30M£0.055,512.00

39.3% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 66.7% of ConvaTec Group shares are held by institutional investors. 30.7% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 20.2% of ConvaTec Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hikma Pharmaceuticals received 446 more outperform votes than ConvaTec Group when rated by MarketBeat users. Likewise, 70.68% of users gave Hikma Pharmaceuticals an outperform vote while only 66.54% of users gave ConvaTec Group an outperform vote.

CompanyUnderperformOutperform
Hikma PharmaceuticalsOutperform Votes
798
70.68%
Underperform Votes
331
29.32%
ConvaTec GroupOutperform Votes
352
66.54%
Underperform Votes
177
33.46%

Summary

Hikma Pharmaceuticals beats ConvaTec Group on 14 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTEC vs. The Competition

MetricConvaTec GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£5.65B£3.16B£4.84B£1.40B
Dividend Yield1.69%1.87%2.96%12.00%
P/E Ratio5,512.00340.96194.351,723.87
Price / Sales2.64212.282,453.28328,440.12
Price / Cash17.01124.3046.7732.82
Price / Book3.322.974.562.53
Net Income£130.30M£99.12M£103.13M£180.05M
7 Day Performance-2.82%-0.13%-0.53%0.81%
1 Month Performance-4.04%-5.25%-5.96%8.89%
1 Year Performance25.96%-3.70%8.29%16.62%

ConvaTec Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIK
Hikma Pharmaceuticals
1.2496 of 5 stars
GBX 1,786
-1.2%
GBX 2,068.75
+15.8%
-1.7%£3.96B£2.88B2,665.679,100News Coverage
SN
Smith & Nephew
2.8677 of 5 stars
GBX 962
+0.4%
GBX 1,362.50
+41.6%
-22.9%£8.41B£5.55B4,008.3318,452High Trading Volume
HCM
HUTCHMED
0 of 5 stars
GBX 268
-6.6%
N/A+9.6%£2.29B£838M2,680.001,988News Coverage
Gap Down
INDV
Indivior
1.4428 of 5 stars
GBX 1,538
-2.1%
GBX 2,515
+63.5%
+5.4%£2.09B£1.09B153,800.001,164News Coverage
AMS
Advanced Medical Solutions Group
1.4483 of 5 stars
GBX 182
-0.8%
GBX 300
+64.8%
-21.4%£395.56M£126.21M2,600.00800Positive News
TSTL
Tristel
0.3333 of 5 stars
GBX 470
flat
GBX 390
-17.0%
+39.3%£223.20M£39.49M3,615.38208High Trading Volume
BVC
BATM Advanced Communications
0 of 5 stars
GBX 19.05
+1.9%
N/A-24.0%£83.09M£122.83M2,800.00980Gap Down
SPEC
INSPECS Group
0 of 5 stars
GBX 47
-4.1%
N/A-52.5%£47.79M£202M-2,350.001,732
CNSL
Cambridge Nutritional Sciences
0 of 5 stars
GBX 3.32
-0.8%
N/AN/A£7.91M£9.05M-332.2091
GNS
Genus
1.8371 of 5 stars
GBX 1,724
-2.2%
GBX 4,500
+161.0%
-38.9%£1.14B£673.10M3,380.393,500Gap Down

Related Companies and Tools

This page (LON:CTEC) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners